Loading…
New strategies for the synthesis of A3 adenosine receptor antagonists
New A(3) adenosine receptor antagonists were synthesized and tested at human adenosine receptor subtypes. An advanced synthetic strategy permitted us to obtain a large amount of the key intermediate 5 that was then submitted to alkylation procedures in order to obtain the derivatives 6-8. These comp...
Saved in:
Published in: | Bioorganic & medicinal chemistry 2003-09, Vol.11 (19), p.4161-4169 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c250t-7a071398948dcf5c887f104deb419c8344cc35bc09d3e8991060ff549fe99b393 |
---|---|
cites | |
container_end_page | 4169 |
container_issue | 19 |
container_start_page | 4161 |
container_title | Bioorganic & medicinal chemistry |
container_volume | 11 |
creator | BARALDI, Pier Giovanni BOVERO, Andrea FRUTTAROLO, Francesca ROMAGNOLI, Romeo MOJGAN AGHAZADEH TABRIZI PRETI, Delia VARANI, Katia BOREA, Pier Andrea MOORMAN, Allan R |
description | New A(3) adenosine receptor antagonists were synthesized and tested at human adenosine receptor subtypes. An advanced synthetic strategy permitted us to obtain a large amount of the key intermediate 5 that was then submitted to alkylation procedures in order to obtain the derivatives 6-8. These compounds were then functionalised into ureas at the 5-position (compounds 9-11, 18 and 19) to evaluate their affinity and selectivity versus hA(3) adenosine receptor subtype; in particular, compounds 18 and 19 displayed a value of affinity of 4.9 and 1.3 nM, respectively. Starting from 5, the synthetic methodologies employed permitted us to perform a rapid and a convenient divergent synthesis. A further improvement allowed the regioselective preparation of the N(8)-substituted compound 7. This method could be used as an helpful general procedure for the design of novel A(3) adenosine receptor antagonists without the difficulty of separating the N(8)-substituted pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines from the corresponding N(7)-isomers. |
doi_str_mv | 10.1016/S0968-0896(03)00484-X |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73601280</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73601280</sourcerecordid><originalsourceid>FETCH-LOGICAL-c250t-7a071398948dcf5c887f104deb419c8344cc35bc09d3e8991060ff549fe99b393</originalsourceid><addsrcrecordid>eNpF0E1Lw0AQgOFFFFurP0HJRdFDdDa7SXaPpdQPKHpQobdls5mtkTapOynSf2_6gT3N5ZkZeBm75HDPgWcP76AzFYPS2S2IOwCpZDw9Yn0uMxkLofkx6_-THjsj-gaARGp-yno80SnnMu-z8Sv-RtQG2-KsQop8E6L2CyNa192giqLGR0MR2RLrhqoao4AOl23HbN3aWVNX1NI5O_F2TnixnwP2-Tj-GD3Hk7enl9FwErskhTbOLeRcaKWlKp1PnVK55yBLLCTXTgkpnRNp4UCXApXWHDLwPpXao9aF0GLAbnZ3l6H5WSG1ZlGRw_nc1tisyOQiA54o6GC6gy40RAG9WYZqYcPacDCbfmbbz2ziGBBm289Mu72r_YNVscDysLUP1oHrPbDk7NwHW7uKDi5NMqFUIv4AWxp3-Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73601280</pqid></control><display><type>article</type><title>New strategies for the synthesis of A3 adenosine receptor antagonists</title><source>ScienceDirect Journals</source><creator>BARALDI, Pier Giovanni ; BOVERO, Andrea ; FRUTTAROLO, Francesca ; ROMAGNOLI, Romeo ; MOJGAN AGHAZADEH TABRIZI ; PRETI, Delia ; VARANI, Katia ; BOREA, Pier Andrea ; MOORMAN, Allan R</creator><creatorcontrib>BARALDI, Pier Giovanni ; BOVERO, Andrea ; FRUTTAROLO, Francesca ; ROMAGNOLI, Romeo ; MOJGAN AGHAZADEH TABRIZI ; PRETI, Delia ; VARANI, Katia ; BOREA, Pier Andrea ; MOORMAN, Allan R</creatorcontrib><description>New A(3) adenosine receptor antagonists were synthesized and tested at human adenosine receptor subtypes. An advanced synthetic strategy permitted us to obtain a large amount of the key intermediate 5 that was then submitted to alkylation procedures in order to obtain the derivatives 6-8. These compounds were then functionalised into ureas at the 5-position (compounds 9-11, 18 and 19) to evaluate their affinity and selectivity versus hA(3) adenosine receptor subtype; in particular, compounds 18 and 19 displayed a value of affinity of 4.9 and 1.3 nM, respectively. Starting from 5, the synthetic methodologies employed permitted us to perform a rapid and a convenient divergent synthesis. A further improvement allowed the regioselective preparation of the N(8)-substituted compound 7. This method could be used as an helpful general procedure for the design of novel A(3) adenosine receptor antagonists without the difficulty of separating the N(8)-substituted pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines from the corresponding N(7)-isomers.</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/S0968-0896(03)00484-X</identifier><identifier>PMID: 12951147</identifier><language>eng</language><publisher>Oxford: Elsevier Science</publisher><subject>Adenosine A3 Receptor Antagonists ; Animals ; Binding, Competitive ; Biological and medical sciences ; CHO Cells ; Cricetinae ; Drug Design ; Humans ; Isomerism ; Medical sciences ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems ; Pharmacology. Drug treatments ; Pyrazoles - chemistry ; Pyrimidines - chemical synthesis ; Pyrimidines - metabolism ; Pyrimidines - pharmacology ; Receptor, Adenosine A3 - metabolism ; Structure-Activity Relationship ; Triazoles - chemistry</subject><ispartof>Bioorganic & medicinal chemistry, 2003-09, Vol.11 (19), p.4161-4169</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c250t-7a071398948dcf5c887f104deb419c8344cc35bc09d3e8991060ff549fe99b393</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15263882$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12951147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BARALDI, Pier Giovanni</creatorcontrib><creatorcontrib>BOVERO, Andrea</creatorcontrib><creatorcontrib>FRUTTAROLO, Francesca</creatorcontrib><creatorcontrib>ROMAGNOLI, Romeo</creatorcontrib><creatorcontrib>MOJGAN AGHAZADEH TABRIZI</creatorcontrib><creatorcontrib>PRETI, Delia</creatorcontrib><creatorcontrib>VARANI, Katia</creatorcontrib><creatorcontrib>BOREA, Pier Andrea</creatorcontrib><creatorcontrib>MOORMAN, Allan R</creatorcontrib><title>New strategies for the synthesis of A3 adenosine receptor antagonists</title><title>Bioorganic & medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>New A(3) adenosine receptor antagonists were synthesized and tested at human adenosine receptor subtypes. An advanced synthetic strategy permitted us to obtain a large amount of the key intermediate 5 that was then submitted to alkylation procedures in order to obtain the derivatives 6-8. These compounds were then functionalised into ureas at the 5-position (compounds 9-11, 18 and 19) to evaluate their affinity and selectivity versus hA(3) adenosine receptor subtype; in particular, compounds 18 and 19 displayed a value of affinity of 4.9 and 1.3 nM, respectively. Starting from 5, the synthetic methodologies employed permitted us to perform a rapid and a convenient divergent synthesis. A further improvement allowed the regioselective preparation of the N(8)-substituted compound 7. This method could be used as an helpful general procedure for the design of novel A(3) adenosine receptor antagonists without the difficulty of separating the N(8)-substituted pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines from the corresponding N(7)-isomers.</description><subject>Adenosine A3 Receptor Antagonists</subject><subject>Animals</subject><subject>Binding, Competitive</subject><subject>Biological and medical sciences</subject><subject>CHO Cells</subject><subject>Cricetinae</subject><subject>Drug Design</subject><subject>Humans</subject><subject>Isomerism</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrazoles - chemistry</subject><subject>Pyrimidines - chemical synthesis</subject><subject>Pyrimidines - metabolism</subject><subject>Pyrimidines - pharmacology</subject><subject>Receptor, Adenosine A3 - metabolism</subject><subject>Structure-Activity Relationship</subject><subject>Triazoles - chemistry</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpF0E1Lw0AQgOFFFFurP0HJRdFDdDa7SXaPpdQPKHpQobdls5mtkTapOynSf2_6gT3N5ZkZeBm75HDPgWcP76AzFYPS2S2IOwCpZDw9Yn0uMxkLofkx6_-THjsj-gaARGp-yno80SnnMu-z8Sv-RtQG2-KsQop8E6L2CyNa192giqLGR0MR2RLrhqoao4AOl23HbN3aWVNX1NI5O_F2TnixnwP2-Tj-GD3Hk7enl9FwErskhTbOLeRcaKWlKp1PnVK55yBLLCTXTgkpnRNp4UCXApXWHDLwPpXao9aF0GLAbnZ3l6H5WSG1ZlGRw_nc1tisyOQiA54o6GC6gy40RAG9WYZqYcPacDCbfmbbz2ziGBBm289Mu72r_YNVscDysLUP1oHrPbDk7NwHW7uKDi5NMqFUIv4AWxp3-Q</recordid><startdate>20030915</startdate><enddate>20030915</enddate><creator>BARALDI, Pier Giovanni</creator><creator>BOVERO, Andrea</creator><creator>FRUTTAROLO, Francesca</creator><creator>ROMAGNOLI, Romeo</creator><creator>MOJGAN AGHAZADEH TABRIZI</creator><creator>PRETI, Delia</creator><creator>VARANI, Katia</creator><creator>BOREA, Pier Andrea</creator><creator>MOORMAN, Allan R</creator><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030915</creationdate><title>New strategies for the synthesis of A3 adenosine receptor antagonists</title><author>BARALDI, Pier Giovanni ; BOVERO, Andrea ; FRUTTAROLO, Francesca ; ROMAGNOLI, Romeo ; MOJGAN AGHAZADEH TABRIZI ; PRETI, Delia ; VARANI, Katia ; BOREA, Pier Andrea ; MOORMAN, Allan R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c250t-7a071398948dcf5c887f104deb419c8344cc35bc09d3e8991060ff549fe99b393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adenosine A3 Receptor Antagonists</topic><topic>Animals</topic><topic>Binding, Competitive</topic><topic>Biological and medical sciences</topic><topic>CHO Cells</topic><topic>Cricetinae</topic><topic>Drug Design</topic><topic>Humans</topic><topic>Isomerism</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrazoles - chemistry</topic><topic>Pyrimidines - chemical synthesis</topic><topic>Pyrimidines - metabolism</topic><topic>Pyrimidines - pharmacology</topic><topic>Receptor, Adenosine A3 - metabolism</topic><topic>Structure-Activity Relationship</topic><topic>Triazoles - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BARALDI, Pier Giovanni</creatorcontrib><creatorcontrib>BOVERO, Andrea</creatorcontrib><creatorcontrib>FRUTTAROLO, Francesca</creatorcontrib><creatorcontrib>ROMAGNOLI, Romeo</creatorcontrib><creatorcontrib>MOJGAN AGHAZADEH TABRIZI</creatorcontrib><creatorcontrib>PRETI, Delia</creatorcontrib><creatorcontrib>VARANI, Katia</creatorcontrib><creatorcontrib>BOREA, Pier Andrea</creatorcontrib><creatorcontrib>MOORMAN, Allan R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic & medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BARALDI, Pier Giovanni</au><au>BOVERO, Andrea</au><au>FRUTTAROLO, Francesca</au><au>ROMAGNOLI, Romeo</au><au>MOJGAN AGHAZADEH TABRIZI</au><au>PRETI, Delia</au><au>VARANI, Katia</au><au>BOREA, Pier Andrea</au><au>MOORMAN, Allan R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New strategies for the synthesis of A3 adenosine receptor antagonists</atitle><jtitle>Bioorganic & medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>2003-09-15</date><risdate>2003</risdate><volume>11</volume><issue>19</issue><spage>4161</spage><epage>4169</epage><pages>4161-4169</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>New A(3) adenosine receptor antagonists were synthesized and tested at human adenosine receptor subtypes. An advanced synthetic strategy permitted us to obtain a large amount of the key intermediate 5 that was then submitted to alkylation procedures in order to obtain the derivatives 6-8. These compounds were then functionalised into ureas at the 5-position (compounds 9-11, 18 and 19) to evaluate their affinity and selectivity versus hA(3) adenosine receptor subtype; in particular, compounds 18 and 19 displayed a value of affinity of 4.9 and 1.3 nM, respectively. Starting from 5, the synthetic methodologies employed permitted us to perform a rapid and a convenient divergent synthesis. A further improvement allowed the regioselective preparation of the N(8)-substituted compound 7. This method could be used as an helpful general procedure for the design of novel A(3) adenosine receptor antagonists without the difficulty of separating the N(8)-substituted pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines from the corresponding N(7)-isomers.</abstract><cop>Oxford</cop><pub>Elsevier Science</pub><pmid>12951147</pmid><doi>10.1016/S0968-0896(03)00484-X</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0968-0896 |
ispartof | Bioorganic & medicinal chemistry, 2003-09, Vol.11 (19), p.4161-4169 |
issn | 0968-0896 1464-3391 |
language | eng |
recordid | cdi_proquest_miscellaneous_73601280 |
source | ScienceDirect Journals |
subjects | Adenosine A3 Receptor Antagonists Animals Binding, Competitive Biological and medical sciences CHO Cells Cricetinae Drug Design Humans Isomerism Medical sciences Neuropharmacology Neurotransmitters. Neurotransmission. Receptors Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems Pharmacology. Drug treatments Pyrazoles - chemistry Pyrimidines - chemical synthesis Pyrimidines - metabolism Pyrimidines - pharmacology Receptor, Adenosine A3 - metabolism Structure-Activity Relationship Triazoles - chemistry |
title | New strategies for the synthesis of A3 adenosine receptor antagonists |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A20%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20strategies%20for%20the%20synthesis%20of%20A3%20adenosine%20receptor%20antagonists&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=BARALDI,%20Pier%20Giovanni&rft.date=2003-09-15&rft.volume=11&rft.issue=19&rft.spage=4161&rft.epage=4169&rft.pages=4161-4169&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/S0968-0896(03)00484-X&rft_dat=%3Cproquest_cross%3E73601280%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c250t-7a071398948dcf5c887f104deb419c8344cc35bc09d3e8991060ff549fe99b393%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73601280&rft_id=info:pmid/12951147&rfr_iscdi=true |